Q&A With Kate Dawson From Biogen: Tecfidera Continues To Show Positive Results For Multiple Sclerosis Patients

Video

Tecfidera has been on the market for a few years to help treat relapsing remitting multiple sclerosis and through extended studies and watching the market positive results have been seen by patients using the oral treatment.

Tecfidera has been on the market for a few years to help treat relapsing remitting multiple sclerosis and through extended studies and watching the market positive results have been seen by patients using the oral treatment.

Kate Dawson, MD, the Vice President of the US Medical Group for Biogen discussed continued reearch on the treatment during the annual ECTRIMS conference in Barcelona.

Recent Videos
Arshad Khanani, MD: Four-Year Outcomes of Faricimab for DME in RHONE-X | Image Credit: Sierra Eye Associates
Dilraj Grewal, MD: Development of MNV in Eyes with Geographic Atrophy in GATHER | Image Credit: Duke Eye Center
Margaret Chang, MD: Two-Year Outcomes of the PDS for Diabetic Retinopathy | Image Credit: Retina Consultants Medical Group
Carl C. Awh, MD: | Image Credit:
Raj K. Maturi, MD: 4D-150 for nAMD in PRISM Population Extension Cohort | Image Credit: Retina Partners Midwest
Charles C. Wykoff, MD, PhD: Interim Analysis on Ixo-Vec Gene Therapy for nAMD | Image Credit: Retina Consultants of Texas
Sunir J. Garg, MD: Pegcetacoplan Preserves Visual Function on Microperimetry | Image Credit: Wills Eye Hospital
Edward H. Wood, MD: Pharmacodynamics of Subretinal RGX-314 for Wet AMD | Image Credit: Austin Retina Associates
Dilsher Dhoot, MD: OTX-TKI for NPDR in Interim Phase 1 HELIOS Results  | Image Credit: LinkedIn
Katherine Talcott, MD: Baseline EZ Integrity Features Predict GA Progression | Image Credit: LinkedIn
© 2024 MJH Life Sciences

All rights reserved.